Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Alkermes plc (ALKS : NSDQ)
 
 • Company Description   
Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.

Number of Employees: 2,211

 
 • Price / Volume Information   
Yesterday's Closing Price: $30.00 Daily Weekly Monthly
20 Day Moving Average: 1,946,925 shares
Shares Outstanding: 163.43 (millions)
Market Capitalization: $4,902.81 (millions)
Beta: 0.75
52 Week High: $33.00
52 Week Low: $21.24
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.53% 15.47%
12 Week 21.21% 33.25%
Year To Date 28.98% 54.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 BURLINGTON ROAD CONNAUGHT HOUSE
-
DUBLIN,L2 DUBLIN 4
IRL
ph: 353-1772-8000
fax: 781-890-0524
investor_relations@alkermes.com http://www.alkermes.com
 
 • General Corporate Information   
Officers
Richard F. Pops - Chairman and Chief Executive Officer
Iain M. Brown - Senior Vice President; Chief Financial Officer
Emily Peterson Alva - Director
David W. Anstice - Director
Shane M. Cooke - Director

Peer Information
Alkermes plc (CORR.)
Alkermes plc (RSPI)
Alkermes plc (CGXP)
Alkermes plc (BGEN)
Alkermes plc (GTBP)
Alkermes plc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G01767105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 163.43
Most Recent Split Date: 5.00 (2.00:1)
Beta: 0.75
Market Capitalization: $4,902.81 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 25.09% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 120.00
PEG Ratio: -
Price Ratios
Price/Book: 4.56
Price/Cash Flow: 40.72
Price / Sales: 4.08
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -92.31%
Sales Growth
vs. Year Ago Period: 10.78%
vs. Previous Quarter: -14.15%
ROE
03/31/22 - 3.87
12/31/21 - 3.95
09/30/21 - 1.26
ROA
03/31/22 - 2.13
12/31/21 - 2.20
09/30/21 - 0.70
Current Ratio
03/31/22 - 2.19
12/31/21 - 2.25
09/30/21 - 2.32
Quick Ratio
03/31/22 - 1.86
12/31/21 - 1.93
09/30/21 - 2.02
Operating Margin
03/31/22 - 3.53
12/31/21 - 3.67
09/30/21 - 1.20
Net Margin
03/31/22 - -5.13
12/31/21 - -4.10
09/30/21 - -8.12
Pre-Tax Margin
03/31/22 - -5.47
12/31/21 - -3.35
09/30/21 - -7.19
Book Value
03/31/22 - 6.58
12/31/21 - 6.88
09/30/21 - 6.78
Inventory Turnover
03/31/22 - 1.46
12/31/21 - 1.41
09/30/21 - 1.40
Debt-to-Equity
03/31/22 - 0.27
12/31/21 - 0.26
09/30/21 - 0.27
Debt-to-Capital
03/31/22 - 21.36
12/31/21 - 20.83
09/30/21 - 21.12
 

Powered by Zacks Investment Research ©